Assessment of Relative Bioavailability of Moroctocog Alfa and Moroctocog Alfa (AF-CC) in Subjects With Severe Hemophilia A.

about

Assessment of Relative Bioavailability of Moroctocog Alfa and Moroctocog Alfa (AF-CC) in Subjects With Severe Hemophilia A.

Item

http://www.wikidata.org/entity/Q53835196

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Assessment of Relative Bioavai ...... ects With Severe Hemophilia A.

@en

Assessment of Relative Bioavailability of Moroctocog Alfa and Moroctocog Alfa

@nl

type

Item

label

Assessment of Relative Bioavai ...... ects With Severe Hemophilia A.

@en

Assessment of Relative Bioavailability of Moroctocog Alfa and Moroctocog Alfa

@nl

prefLabel

Assessment of Relative Bioavai ...... ects With Severe Hemophilia A.

@en

Assessment of Relative Bioavailability of Moroctocog Alfa and Moroctocog Alfa

@nl

P1476

Assessment of Relative Bioavai ...... ects With Severe Hemophilia A.

@en

P2093

Anna Plotka

http://www.w3.org/2001/XMLSchema#string

Jeremy Rupon

http://www.w3.org/2001/XMLSchema#string

Joan Korth-Bradley

http://www.w3.org/2001/XMLSchema#string

Pablo Rendo

http://www.w3.org/2001/XMLSchema#string

Robert Charnigo

http://www.w3.org/2001/XMLSchema#string

P2860

Impact of being underweight or overweight on factor VIII dosing in hemophilia A patients.

A large region (approximately equal to 95 kDa) of human factor VIII is dispensable for in vitro procoagulant activity.

An improved manufacturing process for Xyntha/ReFacto AF.

Modern haemophilia care.

Predicting dose sparing benefit and bleeding risk of pharmacokinetic-based personalized prophylactic dosing of factor VIII products.

Outcome of Clinical Trials with New Extended Half-Life FVIII/IX Concentrates.

Clinical evaluation of moroctocog alfa (AF-CC), a new generation of B-domain deleted recombinant factor VIII (BDDrFVIII) for treatment of haemophilia A: demonstration of safety, efficacy, and pharmacokinetic equivalence to full-length recombinant fa

BDDrFVIII (Moroctocog alfa [AF-CC]) for surgical haemostasis in patients with haemophilia A: results of a pivotal study.

In vivo recovery of factor VIII and factor IX: intra- and interindividual variance in a clinical setting.

ReFacto and Advate: a single-dose, randomized, two-period crossover pharmacokinetics study in subjects with haemophilia A.

P304

283-288

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/CTS.12544

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-03-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29575770

http://www.w3.org/2001/XMLSchema#string

P932

5944578

http://www.w3.org/2001/XMLSchema#string